The case for Option B and Optional B+: Ensuring that South Africa's commitment to eliminating mother-to-child transmission of HIV becomes a reality

Southern African Journal of HIV Medicine

Volumn 13, Issue 4, 2012, Pages 178-181

  Besada, D ^a   Van Cutsem, G ^b   Goemaere, E ^b   Ford, N ^a   Bygrave, H ^a   Lynch, S ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS TENOFOVIR; LAMIVUDINE; TENOFOVIR; UNCLASSIFIED DRUG;

BREAST FEEDING; DRUG COST; GOVERNMENT; HEALTH CARE PLANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; SOUTH AFRICA; VERTICAL TRANSMISSION;

EID: 84873878862     PISSN: 16089693     EISSN: 20786751     Source Type: Journal    
DOI: 10.7196/SAJHIVMED.864     Document Type: Review

References (35)

1. Pillay P, Black V. Safety, strength and simplicity of efavirenz in pregnancy. Southern African Journal of HIV Medicine 2012;13(1):28-33.
2. World Health Organization (WHO). Programmatic Update: Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. Geneva: WHO, 2012. http://www.who.int/hiv/pub/mtct/programmatic- update2012/en/index.html (accessed 18 October 2012).
3. Presidential Emergency Plan for AIDS Relief (PEPFAR) Scientific Advisory Board. Recommendations for the Office of the US Global AIDS Coordinator: Implications of HPTN 052 for PEPFAR's Treatment Programs 2011. Washington: PEPFAR, 2011. http://www.pepfar.gov/documents/organization/177126.pdf (accessed 23 April 2012).
4. Bachman G, Phelps BR. PMTCT and Community: Updates and PEPFAR Perspectives. Presentations from the CCABA/UNICEF/UNAIDS/Global Fund/RIATT 'Road to Washington' meeting in London, 28 February 2012. http://www.ccaba.org/wp- content/uploads/Bachman-and-Phelps-presentation.pdf (accessed 18 October 2012).
5. UNICEF, Business Leadership Council. A Business Case for Options B and B+ to Eliminate Mother to Child Transmission of HIV by 2015. http://www.unicef. org/aids/files/discussion-paper.a-business-case-for-options-b.pdf (accessed 22 August 2012).
6. Zolfo M, De Weggheleire A, Schouten E, et al. Time for 'test and treat' in prevention of mother-to-child transmission programs in low- and middle-income countries. J Acquir Immune Defic Syndr 2010;55(3):287-289. [http://dx.doi.org/ 10.1097/QAI.0b013e3181eef3da]
7. World Health Organization (WHO). Use of Efavirenz During Pregnancy: A Public Health Perspective. Technical Update on Treatment Optimization. Geneva: WHO, 2012. http://www.who.int/hiv/pub/treatment2/efavirenz/en/index.html (accessed 1 June 2012).
8. Medical Research Council (MRC). Media Advisory - Second South African Prevention of Mother to Child Transmission Evaluation Shows Reduction in Perinatal (Early) Mother to Child Transmission of HIV. Pretoria: MRC, 2012.
9. Rosen S, Fox M. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Medicine 2011;8(7):e100105. [http://dx.doi.org/10.1371/journal.pmed.1001056]
10. United Nations Children's Fund (UNICEF). South Africa Statistics. Pretoria: UNICEF, 2009. http://www.unicef.org/infobycountry/southafrica- statistics.html (accessed 18 October 2012).
11. World Health Organization (WHO). World Health Statistics 2009. Geneva: WHO, 2009. http://www.who.int/whosis/whostat/2009/en/index.html (accessed 18 October 2012).
12. Kranzer K, Ford N. Unstructured treatment interruption of antiretroviral therapy in clinical practice: A systematic review. Trop Med Int Health 2011;16(10):1297. [http://dx.doi.org/10.1111/j.1365-3156.2011.02828.x]
13. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355(22):2283-2296.
14. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: Results of the Staccato randomised trial. Lancet 2006;368(9534):459-465. [http://dx.doi.org/10.1016/S0140-6736(06)69153-8]
15. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed 10 April 2012).
16. European AIDS Clinical Society. European Guidelines for treatment of HIV infected adults in Europe, 2011. http://www.europeanaidsclinicalsociety.org/ index.php?option=com-content&view=article&id=59&Itemid=41 (accessed 18 October 2012).
17. Hargrove JW, Humphrey J. Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe. AIDS 2010;24(3):F11-F14. [http://dx.doi.org/10.1097/QAD.0b013e328335749d]
18. Bradshaw D, Dorrington RE, Laubscher R. Rapid Mortality Surveillance Report 2011. Cape Town: Medical Research Council, 2012.
19. Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000 - 2006. AIDS 2008;22(8):973-981. [http://dx.doi.org/10.1097/QAD.0b013e3282f9b67a].
20. Hoffman RM, Black V, Technau K, et al. Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa. J Acquir Immune Defic Syndr 2010;54(1):35-41. [http://dx.doi.org/10.1097/QAI.0b013e3181cf9979].
21. Lingappa JR, Lambdin B, Bukusi EA, et al. Regional differences in prevalence of HIV-1 discordance in Africa and enrolment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS ONE 2008;3(1):e1411. [http://dx.doi.org/10.1371/journal.pone.0001411].
22. Eyawo O, de Walque D, Ford N, et al. HIV status in discordant couples in sub-Saharan Africa: A systematic review and meta-analysis. Lancet Infect Dis 2010;10(11):770-777. [http://dx.doi.org/10.1016/S1473-3099(10)70189-4]
23. Donnell D, Beaten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: A prospective cohort analysis. Lancet 2010;375(9731):2092-2098. [http://dx.doi.org/10.1016/S0140-6736(10)60705- 2]
24. World Health Organization (WHO). Guidance on Couples HIV Testing and Counselling Including Antiretroviral Therapy for Treatment and Prevention in Serodiscordant Couples: Recommendations for a Public Health Approach. Geneva: WHO, 2012. http://apps.who.int/iris/bitstream/10665/44646/1/9789241501972-eng. pdf (accessed 18 October 2012).
25. Schouten EJ, Jahn A, Midiani D, et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: Time for a public health approach. Lancet 2011;378(9787):282-284. [http://dx.doi.org/10.1016/S0140-6736(10)62303-3]
26. El-Khatib Z, Ekstrom AM, Coovadia A, et al. Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg. South Africa - a prospective cohort study. BMC Public Health 2011;11:88. [http://dx.doi.org/10.1186/1471-2458-11-88]
27. Igwegbe AO, Ugboaja JO, Nwajiaku LA. Prevalence and determinants of nonadherence to antiretroviral therapy among HIV-positive pregnant women in Nnewi, Nigeria. International Journal of Medicine and Medical Sciences 2010;2(8):238-245.
28. Awiti, UO, Ekström AM, Ilako F Indalo D, Wamalwa D, Rubenson B. Reasoning and deciding PMTCT-adherence during pregnancy among women living with HIV in Kenya. Cult Health Sex 2011;13(7):829-840. [http://dx.doi.org/10.1080/ 13691058.2011.583682]
29. Mepham S, Zondi Z, Mbuvazi A, Mkhwanazi N, Newell ML. Challenges in PMTCT antiretroviral adherence in northern KwaZulu-Natal, South Africa. AIDS Care 2011;23(6):741-747. [http://dx.doi.org/10.1080/09540121.2010.516341]
30. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: A systematic review and meta-analysis. AIDS 2012;26(16):2039-2052.
31. Myer L, Cornell M, Fox M. Loss to follow up and mortality among pregnant and non-pregnant women initiating ART across South Africa. http://www. retroconference.org/2012b/Abstracts/44356.htm (accessed 18 October 2012).
32. Médecins Sans Frontières (MSF) Access Campaign. Untangling the web of Antiretroviral Price Reductions. 15th Edition. Geneva: MSF Access Campaign, 2012. http://d2pd3b5abq75bb.cloudfront.net/2012/09/20/11/46/41/289/ MSF-Access-UTW-15th-Edition-2012-updated18-09-12.pdf (accessed 18 October 2012).
33. World Health Organization (WHO). The Strategic Use of Antiretrovirals for Treatment And Prevention of HIV Infection. Geneva: WHO, 2011. http://www.who.int/hiv/pub/meetingreports/consultation-20111116/en/index.html (accessed 20 October 2012).
34. Struik GM, den Exter RA, Munthali C, et al. The prevalence of renal impairment among adults with early HIV disease in Blantyre, Malawi. Int J STD AIDS 2011;22(8):457-462. [http://dx.doi.org/10.1258/ijsa.2011.010521]
35. Siberry GK, Williams PL, Mendez H, et al. Safety of tenofovir use during pregnancy: Early growth outcomes in HIV-exposed uninfected infants. AIDS 2012;26(9):1151-1159.